Table 1 Clinical and serological features and current therapy of SLE patients
Characteristic | |
|---|---|
Height (mean ± standard deviation; cm) | 163 ± 6 |
Weight (mean ± standard deviation; kg) | 59 ± 9 |
Body mass index (mean ± standard deviation) | 23 ± 4 |
Acute cutaneous lupus [n/tot (%)] | 28/61 (46) |
Subacute cutaneous lupus [n/tot (%)] | 11/61 (18) |
Discoid lupus [n/tot (%)] | 5/61 (8) |
Photosensitivity [n/tot (%)] | 31/61 (51) |
Serositis [n/tot (%)] | 12/61 (20) |
Neuropsychiatric lupus [n/tot (%)] | 2/61 (3) |
Arthritis [n/tot (%)] | 39/61 (64) |
Glomerulonephritis [n/tot (%)] | 20/61 (33) |
Hematological features [n/tot (%)] | 32/61 (52) |
Arterial thrombosis [n/tot (%)] | 1/61 (2) |
Venous thrombosis [n/tot(%)] | 1/61 (2) |
Pregnancy morbidity [n/tot (%)] | 6/61 (10) |
Secondary anti-phospholipid syndrome [n/tot (%)] | 6/61 (10) |
ANA [n/tot (%)] | 61/61 (100) |
Anti-dsDNA [n/tot (%)] | 46/61 (75) |
Anti-Sm [n/tot (%)] | 20/61 (33) |
LA [n/tot (%)] | 11/61 (18) |
aCL IgG [n/tot (%)] | 15/61 (25) |
aCL IgM [n/tot(%)] | 13/61 (21) |
aβ2GPI IgG [n/tot (%)] | 9/61 (15) |
aβ2GPI IgM [n/tot (%)] | 6/61 (10) |
Anti-malarials [n/tot (%)] | 42/61 (69) |
Prednisone [n/tot (%)] | 43/61 (70) |
Immunosuppressants [n/tot (%)] | 20/61 (33) |